research use only

Almonertinib (HS-10296) EGFR inhibitor

Name: Almonertinib (HS-10296)
Brand: Selleck Chemicals
SKU: S8817
Availability: InStock
Rating: 5 (4 reviews)

Cat.No.S8817

Almonertinib (HS-10296) is a small molecule inhibitor of EGFR-activating mutations and T790M-resistant mutation with limited activity against wild-type EGFR.

Chemical Structure

Molecular Weight: 525.64

Jump to

Quality Control

Batch: S881701 DMSO]100 mg/mL]false]Ethanol]6 mg/mL]false]Water]Insoluble]false Purity: 99.98%

Cited in Nature Medicine for its top-tier quality
COA
NMR
SDS
Datasheet

99.98

Related Targets	VEGFR PDGFR FGFR c-Met Src MEK CSF-1R FLT3 HER2 c-Kit
Other EGFR Inhibitors	Sunvozertinib Icotinib Hydrochloride AG-490 AG-1478 Canertinib (CI-1033) Rociletinib (CO-1686) WZ4002 Genistein Poziotinib (NOV120101, HM781-36B) PD153035

Solubility

In vitro
Batch:

DMSO : 100 mg/mL (190.24 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 6 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	5.000mg/ml (9.51mM)	Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	1.250mg/ml (2.38mM)	Taking the 1 mL working solution as an example, add 50 μL of 25 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	525.64	Formula	C₃₀H₃₅N₇O₂	Storage (From the date of receipt)	3 years -20°C powder
CAS No.	1899921-05-1	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	Aumolertinib			Smiles	CN(C)CCN(C)C1=CC(=C(C=C1NC(=O)C=C)NC2=NC=CC(=N2)C3=CN(C4=CC=CC=C43)C5CC5)OC

Mechanism of Action

Targets/IC₅₀/Ki	EGFR-sensitizing mutation EGFR-T790M resistance mutation
References	[1] https://pubmed.ncbi.nlm.nih.gov/32916310/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04841811	Recruiting	Lung Cancer	Guangdong Association of Clinical Trials\|Jiangsu Hansoh Pharmaceutical Co. Ltd.	June 20 2022	Phase 3
NCT04882345	Unknown status	Lung Cancer\|EGFR Gene Mutation	Shanghai Chest Hospital\|Jiangsu Hansoh Pharmaceutical Co. Ltd.	July 15 2021	Phase 2
NCT04944069	Not yet recruiting	NSCLC\|Leptomeningeal Metastasis\|EGFR Activating Mutation	Second Affiliated Hospital of Nanchang University\|Jiangsu Hansoh Pharmaceutical Co. Ltd.	July 2021	Not Applicable
NCT04870190	Not yet recruiting	NSCLC	Shanghai Chest Hospital	June 1 2021	Phase 3
NCT04354961	Recruiting	Pulmonary Adenosquamous Carcinoma	Fujian Cancer Hospital\|Jiangsu Hansoh Pharmaceutical Co. Ltd.	May 7 2021	Phase 2
NCT04687241	Active not recruiting	Non-small Cell Lung Cancer	Jiangsu Hansoh Pharmaceutical Co. Ltd.	April 30 2021	Phase 3

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):